Drug Profile
Omecamtiv mecarbil - Cytokinetics
Alternative Names: AMG-423; CK-1827452; CK-452Latest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Cytokinetics
- Developer Amgen; Cytokinetics; Servier
- Class Amines; Carboxylic acids; Esters; Fluorobenzenes; Heart failure therapies; Ischaemic heart disorder therapies; Organic chemicals; Piperazines; Pyridines; Small molecules
- Mechanism of Action Cardiac myosin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Chronic heart failure
- Phase III Heart failure
- Phase II Acute heart failure
- No development reported Angina pectoris; Cardiomyopathies
Most Recent Events
- 27 Feb 2024 Cytokinetics anticipates to receive the CHMP opinion for the Marketing Authorization Application (MAA) of omecamtiv mecarbil in the second quarter of 2024
- 27 Feb 2024 Cytokinetics submits a response to EMA’s Day 180 list of outstanding issues (LoOIs)
- 31 Dec 2023 Cytokinetics receives Day 180 list of outstanding issues from the European Medicines Agency (EMA) for omecamtiv mecarbil for Chronic heart failure